First human trial launches for experimental blood cancer drug
NCT ID NCT06372717
Summary
This early-stage study is testing a new drug called APL-4098 in adults with advanced forms of blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see how well the drug works when given alone or combined with standard treatments. The main goals are to check for side effects and determine the right dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hollywood Private Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
-
Royal Perth Hospital
RECRUITINGPerth, Western Australia, 6000, Australia
-
Sarah Cannon Research Institute UK
RECRUITINGLondon, W1G 0PU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Vincent's Hospital Melbourne
RECRUITINGFitzroy, Victoria, 3065, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
-
The Royal Marsden Hospital
RECRUITINGLondon, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.